Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

33 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer.
Scott AM, Wiseman G, Welt S, Adjei A, Lee FT, Hopkins W, Divgi CR, Hanson LH, Mitchell P, Gansen DN, Larson SM, Ingle JN, Hoffman EW, Tanswell P, Ritter G, Cohen LS, Bette P, Arvay L, Amelsberg A, Vlock D, Rettig WJ, Old LJ. Scott AM, et al. Among authors: vlock d. Clin Cancer Res. 2003 May;9(5):1639-47. Clin Cancer Res. 2003. PMID: 12738716 Clinical Trial.
Phase II trial of interferon-alpha in locally recurrent or metastatic squamous cell carcinoma of the head and neck: immunological and clinical correlates.
Vlock DR, Andersen J, Kalish LA, Johnson JT, Kirkwood JM, Whiteside T, Herberman RB, Adams GS, Oken MM, Haselow RE. Vlock DR, et al. J Immunother Emphasis Tumor Immunol. 1996 Nov;19(6):433-42. doi: 10.1097/00002371-199611000-00008. J Immunother Emphasis Tumor Immunol. 1996. PMID: 9041463 Clinical Trial.
Phase III comparison of high-dose paclitaxel + cisplatin + granulocyte colony-stimulating factor versus low-dose paclitaxel + cisplatin in advanced head and neck cancer: Eastern Cooperative Oncology Group Study E1393.
Forastiere AA, Leong T, Rowinsky E, Murphy BA, Vlock DR, DeConti RC, Adams GL. Forastiere AA, et al. Among authors: vlock dr. J Clin Oncol. 2001 Feb 15;19(4):1088-95. doi: 10.1200/JCO.2001.19.4.1088. J Clin Oncol. 2001. PMID: 11181673 Clinical Trial.
Phase Ib trial of the effect of peritumoral and intranodal injections of interleukin-2 in patients with advanced squamous cell carcinoma of the head and neck: an Eastern Cooperative Oncology Group trial.
Vlock DR, Snyderman CH, Johnson JT, Myers EN, Eibling DE, Rubin JS, Kirkwood JM, Dutcher JP, Adams GL. Vlock DR, et al. J Immunother Emphasis Tumor Immunol. 1994 Feb;15(2):134-9. doi: 10.1097/00002371-199402000-00007. J Immunother Emphasis Tumor Immunol. 1994. PMID: 8136946 Clinical Trial.
Decreased tumor blood flow as measured by positron emission tomography in cancer patients treated with interleukin-1 and carboplatin on a phase I trial.
Logan TF, Jadali F, Egorin MJ, Mintun M, Sashin D, Gooding WE, Choi Y, Bishop H, Trump DL, Gardner D, Kirkwood J, Vlock D, Johnson C. Logan TF, et al. Among authors: vlock d. Cancer Chemother Pharmacol. 2002 Dec;50(6):433-44. doi: 10.1007/s00280-002-0517-4. Epub 2002 Oct 1. Cancer Chemother Pharmacol. 2002. PMID: 12451469 Clinical Trial.
33 results